ESHRE PGD Consortium Steering Committee* as which culture medium to use, and emphasizing the role the PGD Consortium could play in setting up guidelines The first clinical application of preimplantation genetic for good laboratory practice. In conclusion, it is clear that diagnosis (PGD) was reported almost a decade ago. Since the effort of gathering data on PGD cycles is worthwhile then, the range of genetic defects that can be detected at and will be continued in the future, preferably using single cell level has increased dramatically. At the 13th electronic data collection.
Committee who would report to the Consortium members on Form (3) a regular basis and hold a meeting each year at the ESHRE Pregnancy data: Ultrasound observations, prenatal diagnosis Annual Meeting. and outcome, pregnancy evolution and any complications, and mode of delivery.
Form (4) Membership and aims of the ESHRE PGD Consortium

Membership of the Consortium is open to all centres actively
Follow-up data: Neonatal parameters, congenital defects and long term developmental follow-up of children. involved in the clinical application of PGD. (Centres at a preclinical stage of PGD development or with a general interest
In addition, on an optional and voluntary basis, forms (5)-(8) are provided for supplying information on embryo biopsy, in the area are encouraged to become members of the Special Interest Group in Reproductive Genetics.) As an ESHRE PCR and FISH protocols and also any relevant publications. At present, hard copies of completed forms are mailed to sponsored activity, the Consortium members are mainly based in Europe though several centres in Australia and the US have ESHRE Central Office for collation by members of the Steering Committee. It is hoped that submission of data can soon be already joined. However, it should be emphasized that it is not the aim of the Consortium to comprehensively survey via the Internet initially in spreadsheet form by e-mail but later directly through a dedicated web site accessed from the PGD on a global basis. Rather, the overall aim is to collate detailed data on a long-term basis from a number of centres main ESHRE site and suitably password protected. Twenty-five centres had registered by the time of the first to increase the statistical significance of any outcome analysis and to promote exchange of information between active clinics.
annual Consortium meeting in Gotëborg in June 1998. At that meeting, it was decided to collect data retrospectively for Members therefore need to be committed to the work involved in this process and be prepared to provide the resources to cycles started in 1997 and the Steering Committee undertook the responsibility of preparing a report based on these data for gather relevant data, for example, in following up children after birth. In return for this effort, members have access to the meeting the following year. More recently, data collection has been extended to 30 September 1998. These data are the anonymous data, protocols and publications and can participate in regular ESHRE sponsored meetings on progress reported here. In future, it is hoped to extend this further both prospectively on an ongoing basis but also retrospectively to in clinical PGD within the Consortium.
The main aims of the Consortium are summarized as follows: include all of the PGD cycles within the Consortium. By June, 1999, 16 centres had provided most of the requested data but To survey the availability of PGD for different conditions facilitating cross-referral of patients. To collect prospectively many had not provided data in all of the areas requested, e.g. several centres had provided data on the PGD cycles, but not and retrospectively data on the accuracy, reliability and effectiveness of PGD. To initiate follow-up studies of pregnancies the referral data of their patients. As the Consortium is an active collaboration, membership of those centres which have and children born. To produce guidelines and recommended PGD protocols to promote best practice. To formulate a failed to provide any data will be deemed to have lapsed subject to the statutes of the PGD Consortium installed at the consensus on the use of PGD.
last ESHRE meeting in Tours in June, 1999 . In those cases where only partial information has been provided, centres will be encouraged to complete their submissions and the data Data collection accumulated as it becomes available. To some extent, this Each centre participating in the Consortium is assigned a failure has been caused by ambiguities in the original forms centre code following completion of a centre registration form.
and misunderstanding of the precise information requested and This can be obtained from ESHRE Central Office or printed the problem may be eliminated as it becomes clearer what from the ESHRE web site (www.eshre.com). A centre pack is data are needed. then sent to the centres containing master copies of eight forms for duplication as necessary. A brief description of the information requested on these forms is as follows:
Preliminary assessment of data for January 1997 to September 1998
Form (1)
As the information obtained from the 16 centres actively Clinical referral data: Patient history (pregnancies, miscarparticipating in the Consortium is not yet complete, we are riages, termination of pregnancies), indication for PGD. Reason able only to present a preliminary assessment of the data. for PGD (e.g. objection to abortion, concurrent infertility).
However, some clear features are already emerging that may The basis of the centre's decision to offer PGD (or not), and have important practical implications for the future developthe reasons for patient's declining PGD. ment of clinical PGD.
Form (1): Referrals Form (2)
Cycle data: Stimulation, embryology and biopsy data. Number A total of 323 referral sheets have been collected over this 2 year period for a wide variety of monogenic (Table I) and of cumulus oocyte complexes, oocytes inseminated, normally fertilized and biopsied. Results of genetic analysis, transfer chromosomal disorders (Table II) (a number of which are not technically feasible at the present time). This is undoubtedly data and pregnancy outcome. Other referrals: mitochondrial encephalopathy (n ϭ 1), none/unknown (n ϭ 2). Klinefelter syndrome/translocation (11;22), translocation (2; 4)/translocation (11;22), translocation (1;3)/sickle cell anaemia and fragile-X syndrome/Duchenne muscular dystrophy. diagnosis. The mean maternal age was 33.7 (n ϭ 283, range 23-54 years), while the mean paternal age was 35.4 (n ϭ 223, The reproductive history of the couples requesting PGD is presented in Table III as the number of couples having 0, 1 range 24-47 years). Table IV summarizes the reasons why the patients requested or more previous pregnancies etc. For example, 105 couples had never had a previous pregnancy, while 53 couples had PGD. As expected, the most important reasons are previous TOP, objections to TOP and concurrent sub-or infertility. had one pregnancy. It is clear that most couples have had one or more pregnancies and only a minority have had healthy Table V shows the decisions reached by the centres in accepting or rejecting the request for PGD. The most frequent reason children; whereas most had personal experience of affected children and termination of pregnancy (TOP) after prenatal for rejecting a PGD is the technical feasibility of the test, means. All centres performed the biopsy at cleavage stages used and in one cycle the embryos were frozen due to Unknown 2 equipment failure which prevented the diagnosis taking place. In two cycles undiagnosed embryos were transferred at the request of the patient. In total pregnancies were detected in followed by the ethical acceptability. Thirty-six couples declined for a variety of reasons (Table VI) .
83 cycles from a total of 306 embryo transfers by raised serum human chorionic gonadotrophin (HCG) and confirmed by the Form (2): Cycles presence of a fetal heart beat using ultrasonography in 67.
Clinical pregnancy rates at the fetal heart stage were therefore Tables VII-X summarize the PGD cycle data from 16 centres and 392 cycles.
22% per embryo transfer, 18% per oocyte retrieval or 17% per cycle. Two cases have been lost to follow-up. One hundred The largest number of cycles for a specific application were for age-related aneuploidy (n ϭ 116) at four centres using and thirty-seven of the remaining embryos were cryopreserved but no frozen embryo cycles or transfers were reported. multicolour FISH. The next most frequent was identification of sex in X-linked disease (n ϭ 112) by either multicolour Form (3): Pregnancies FISH (n ϭ 104) or PCR methods (n ϭ 8). Fifty-one cycles were performed for cystic fibrosis (CF) for patients carrying Because the Consortium is especially interested in the outcome of the pregnancy and the babies born after PGD, various mutations, but mainly DF508. This included cycles from one centre still using IVF rather than intracytoplasmic the centres were asked to report all pregnancy and baby data since the start of their PGD programme, thus the cycle sperm injection (ICSI) which is normal practice to avoid possible sperm DNA contamination. Forty PGD cycles were data and pregnancy data do not entirely concern the same cycles. Data on 82 pregnancies from 12 PGD centres were for chromosome abnormalities, mainly translocations, again using multicolour FISH. Other autosomal recessive diseases reported (Table XI) . Most pregnancies were reported in cycles employing FISH protocols for diagnosis (54/82; 66%) with several reported cycles were β-thalassaemia, Rhesusisoimmunization, spinal muscular atrophy, Tay-Sachs disease, while the remainder involved PCR analysis. The mean age of the pregnant women for which data are available (n ϭ adrenogenital syndrome, as well as one cycle for sickle cell anaemia. A large number of cycles were also performed 44) was 32 years 4 months Ϯ 4 years. A detailed analysis of pregnancy outcome is presented in Table XII . The initial for autosomal dominant diseases: 31 cycles for myotonic dystrophy, 10 for Huntington's chorea, and several cycles for number of pregnancies was 82, including a total of 110 fetal sacs: 58 singleton pregnancies (71%), 21 twin pregnanMarfan's syndrome, osteogenesis imperfecta and CharcotMarie-Tooth disease type 1A. For X-linked diseases, specific cies (25%), two triplets (2%) and one quadruplet pregnancy (1%). Eleven fetal sacs were lost due to a first-trimester PCR diagnoses were performed for Duchenne's and Becker's muscular dystrophy, as well as several cycles for fragile-X.
miscarriage. During the second trimester, one miscarriage (13 weeks) and one stillbirth (24 weeks) occurred. Reduction Of the 392 cycles reported for the period January 1st, 1997 to September 30th, 1998, 26 (7%) were cancelled, mainly due of fetal sacs was performed in the two triplets and in the quadruplet pregnancy. One pregnancy had to be terminated to a poor response, and 366 cycles reached oocyte retrieval. In most cases, acid Tyrode's was used for zona drilling, while because of a misdiagnosis (see also below). Information on ultrasound follow-up was available for 96 three centres used laser drilling and two used mechanical Total cycles  51  6  4  3  2  2  1  31  10  2  1  2  8  5  4  1 Abbreviations used in the table: CF ϭ cystic fibrosis (various mutations), β-Thal ϭ β-thalassaemia, Rh-inc ϭ rhesus incompatibility, SMA ϭ spinal muscular atrophy, TS ϭ Tay-Sachs disease, AGS ϭ adrenogenital syndrome, SS ϭ sickle-cell anaemia, DM ϭ myotonic dystrophy, HD ϭ Huntington's disease, MS ϭ Marfan's syndrome, OI ϭ osteogenesis imperfecta, CMT ϭ Charcot-Marie-Tooth disease, FRAXA ϭ fragile-X syndrome, DMD ϭ Duchenne's muscular dystrophy (specific), OR ϭ oocyte retrieval, AT ϭ acidic Tyrode's, COC ϭ cumulus oocyte complexes *The number inseminated is not accurate as some centres completed the old forms which did not include this field. % transferable and transferred is of the total diagnosed.
out of 110 fetal sacs. The pregnancy evolution of these 110 there is far less preterm labour reported than prematurity in the children. This is due to underreporting of preterm labour fetal sacs is shown in Table XII . Eighty-one showed a normal development, five of which were reduced because of multiple as a maternal complication. At the time of reporting, 63 women had delivered 79 pregnancy. Eleven fetal sacs were lost during the first trimester. A morphological abnormality was found in four fetuses. In children, while eight pregnancies (four singletons and four twins) were still ongoing. No further data are available on one of the triplet pregnancies, two of the fetuses were a monochorial-monoamniotic twin. One of these twins was an these ongoing pregnancies (Table XIV) . In total, 47 (75%) singletons and 16 (24%) twin pregnancies were delivered. acardiacus, while the other twin suffered intrauterine growth retardation (IUGR) due to twin-twin transfusion. In another Fifty-one percent (24/47) of the singleton pregnancies were delivered spontaneously, while 38% (18/47) were delivered by twin pregnancy, one twin was shown to have an exencephaly. The fourth abnormality was a stillbirth at 24 weeks gestation.
Caesarean section. No method of delivery was reported for 5/ 47 singleton deliveries. Only 3/16 twin pregnancies (19%) were Information on pregnancy complications was available for 59 pregnancies (Table XIII) . Eight pregnancies were still delivered spontaneously, while 10/16 (62%) were delivered by section. The mean gestational age at delivery was 37 weeks ongoing at the time of reporting. No information was available for four singleton pregnancies. Most pregnancies were uneventand 3 days (calculated excluding one twin pregnancy for which information is not available). There was no correlation between ful (49/59; 83%). Complications of pregnancy occurred in 17% (10/59); 6/43 (14%) singleton pregnancies and 4/16 (25%) the maternal age and the gestational age at birth. Seventeen out of 62 (27%) deliveries were premature: 13% (6/47) of the twin pregnancies. The most frequent complication was preterm labour (3/59, 5%). Caution must be given for this number:
singletons and 73% (11/15) of the twins. per se in 38% (28/73), 22 of which were twins (Table XV) .
Form (4): Children
Of these premature children, 20 had a low birth weight (Ͻ2500 Care must be taken when evaluating the following data, since g), 17 of which were twins. Only two of these 20 children a large proportion of the data were not reported (see also the had a birth weight below 1000 g (twin born at 24 weeks right column of Table XV ). In total, 79 children were born, gestation), while one child of this group weighed between of which 28 were premature (35%) ( Table V) . The sex ratio 1000 and 1500 g. In eight children, the prematurity was at birth was heavily skewed towards females reflecting the accompanied by other problems. selective transfer of mainly females in X-linked disease: 43
There were three perinatal deaths (one stillbirth, two neonatal females and 27 males. Mean birth weight, length and head deaths; see above). Perinatal mortality rate was 3.8%. At the circumference were 2850 Ϯ 740 g, 48.3 Ϯ 5.3 cm and 32.9 time of reporting, three children were still on the neonatal Ϯ 2.7 cm respectively. The Apgar score was excellent in 41 ward. No follow-up data are available (Table XV) . children (data were unavailable for 36 children). A bad Apgar was observed twice: one child in the triplet pregnancy with Pre-and postnatal confirmation of diagnosis the acranius twin which delivered prematurely at 24 weeks and died of intracranial bleeding and one term child (singleton)
Prenatal testing was performed in 61/110 fetal sacs (Table  XVI) : in 21 cases CVS was used (11 FISH and 10 PCR cases), was observed for 24 h but showed normal development.
Only two malformations were observed at birth (Table XV) : while in 38 cases amniocentesis was used (29 FISH and nine PCR cases) and for two cases the method of prenatal testing one pes equinovarus, which normalized spontaneously, and one exencephaly which was seen prenatally by ultrasound in is unknown. No miscarriages were reported following prenatal testing. Confirmation of the PGD diagnosis was performed a twin pregnancy. This child died within hours following the delivery. There were no neonatal complications in 44/73 postnatally in 11 babies, four of which already had a PND, and two miscarriages: four karyotypes, five sweat tests and children (60%), while complications were observed in 29 (40%) cases. No information was available for six children.
four genetic tests, twice for Tay-Sachs disease, once for Charcot-Marie-Tooth disease and once for cystic fibrosis The most frequent complication at birth was prematurity (miscarriage) were performed. On seven occasions, the postnatal testing was the first confirmation of the PGD. In total, for which confirmation has been carried out.
and members of the Consortium reporting their data. It is of the ESHRE web site before the next annual report is produced. Using electronic data collection, prospective data gathering should become routine and this will greatly enhance the quality of the data.
Forms (5-8): PGD protocols
There has been considerable debate over how the data On a voluntary basis, centres were invited to submit their should be collected, particularly over the issue of when to protocols for embryo biopsy and single cell genetic analysis report each cycle, with some arguing that this should not be subdivided into FISH and PCR protocols. Fifteen centres until the diagnosis has been confirmed and the pregnancy responded, with eight providing protocols in each of these outcome is known. In practice, as data from each cycle are areas. The basic reason behind this initiative was to identify collected from each centre and given a unique identifying code critical differences in the protocols of the most successful (determined by each centre), it is hoped that these data can be centres that could be shared with the Consortium through continuously accumulated including follow up of the children incorporation into standardized protocols with the ultimate at birth and later in development. However, there is still much goal of promoting the use of best practice. In addition, it is to be learned from the initial stages of each cycle and centres hoped to establish baseline standards for embryo biopsy are therefore encouraged to submit the referral and cycle data (similar to those commonly in use for intracytoplasmic sperm as soon as possible. injection) and single cell analysis both in terms of preliminary Given the diversity of single gene defects, it is perhaps not work up and clinical application.
surprising that many referrals were for conditions for which It was clear that most centres were still using the original PGD is not yet available and conversely that the highest approach of day 3 post-insemination biopsy at cleavage stages referral rates should be for common diseases and/or those that following zona drilling by acid Tyrode's solution (Handyside are currently available (Tables I and II ). The number of et al., 1990). However, there were significant differences in referrals for aneuploidy screening is not representative and the media used (reflecting the practice of individual centres) will certainly increase as more centres offer this form of PGD and about half of the responding centres were now using to women of advanced maternal age, repeated IVF failure and calcium-and magnesium-free media to decompact embryos other indications. prior to biopsy. The criteria (if any) for cancelling a cycle
The reproductive history of couples requesting PGD (Table  because too few follicles, oocytes or embryos were available III) confirms that many have had affected children and only a varied widely. Working practice in terms of the number of minority have healthy children. Most couples have had one or blastomeres removed varied widely, as did whether or not it more previous pregnancies and about a third have had a was considered worthwhile to re-biopsy embryos.
termination of an affected pregnancy. This is reflected in the Most centres employed FISH primarily for identification of average maternal and paternal ages (33.7 and 35.4 respectively). sex in X-linked disease. Over half, however, were also Although pregnancy rates following IVF in women of this age attempting the detection of unbalanced karyotypes in translocaare reasonable, it is clear that if younger women elected to tion carriers and three centres used multicolour FISH to have PGD at an earlier stage, possibly as a result of screening screen for the common aneuploidies causing miscarriage and programmes for common diseases, the prospects for a successcongenital abnormality. Surveying the PCR protocols, it is clear ful outcome could be improved. that most are still based on nested protocols and conventional PGD should be regarded as an option for couples at high methods for mutation detection. However, half of the risk of having a genetically abnormal child. PGD is an extra responding centres were now using fluorescence PCR for alternative, since couples can also opt for prenatal diagnosis, mutation detection and/or linkage analysis. Strikingly, there donor insemination or refrain from having children. The remains no consensus over optimal lysis buffers to use for major differences between PGD and prenatal diagnosis during single cell PCR and this is a critical aspect of PCR protocols established pregnancy are the avoidance of selective terminawhich could be addressed by the Consortium. tion on the one hand and the use of IVF or ICSI on the other. In this respect, it is interesting to note that about one third of Conclusions the couples from this series have had personal experience with termination of pregnancy which was one of the reasons for This first preliminary report and assessment of the current clinical status of PGD within the ESHRE PGD Consortium referral (Table IV) . From the data presented in Table II , it is clear that about 50 couples had multiple (up to six) terminations has taken a lot of time and effort from the Steering Committee of pregnancy. A much larger group (two out of every three from treatment because of aspects connected to IVF or ICSI treatment. couples) was referred because of objection to abortion on moral or religious grounds.
In this series, only centres performing PGD at the cleavage stage have participated, so no data are available on the results PGD also offers opportunities to couples with sub-or infertility and a concurrent genetic risk (Pembrey, 1998): for of polar body biopsy to make any comparison between both methods. Similarly the reported experience with other example, for couples where the woman had a tubal ligation because PND was not available at the time or for couples variations of the standard protocol are too few to make solid conclusions. However, it is clear that one of the most important undergoing IVF treatment and who have a concurrent genetic risk. The first group is very small (only two patients) and will contributions that the Consortium can make is to take initiatives proactively on a multicentre basis to provide the statistical eventually disappear. The second is much larger, about onethird of the couples in our series, and its proportion will power to investigate all aspects of methodology to establish best practice in all aspects of PGD. most probably increase. The patients referred for age-related aneuploidy screening belong to a separate group, although Overall, the pregnancy rates are disappointing (Tables VII-X) . The clinical pregnancy rate for all reported PGD cycles they also need infertility treatment, because they have a much lower risk of abnormal children. The screening is mainly was 71/403 (17.6%). This compares to world-wide pregnancy rates of 25% per cycle (n ϭ 134) and 30% per transfer reported carried out to increase the pregnancy rates and this is why it has to be considered whether this indication needs a separate in 1994 (Harper and Handyside, 1994) , 25% per cycle (n ϭ 197) and 29% per transfer to February, 1995 (Harper, 1996 registry. Indeed, it has been suggested that aneuploidy screening should be referred to as preimplantation genetic screening and, most recently, 20% per cycle (n ϭ 569) and 26% per transfer to January, 1997 (Harper, personal communication) . (PGS) to distinguish it from PGD. In the near future, the numbers of patients in this group will rapidly increase.
These rates appear even lower when compared to pregnancy rates after ICSI in infertile couples (28% per cycle) (Tarlatzis From the centre decisions (Table V) and the reasons for declining (Table VI) , one might get the impression that the and Bili, 1998). The reasons for this low success are manifold and complex but worthy of detailed consideration since without vast majority of all cases are suitable for IVF, technically possible and clinically acceptable. However, it should be noted a reasonable prospect of establishing a pregnancy, at risk couples, who are generally fertile, are unlikely to choose PGD that the picture which emerges from these data is most likely only incompletely representative of the true situation. As stated to avoid the risk of having affected children. Table VII summarizes the Consortium experience (16 above, there must have been many more referrals since the Consortium data base contains more cycles than referrals and centres) with PCR detection of single gene defects. For most genetic defects, only a handful of cycles (n ϭ 1-10) have some centres fail to provide referral data for their patients. The prospective data collection, which will start in the near been reported and technical aspects of these tests can only be evaluated with more experience. For cystic fibrosis (CF) (n ϭ future, will circumvent this problem. Only then will it become clear what the true number of patients is that have declined 51) and myotonic dystrophy (DM) (n ϭ 31), however, the series are larger. Pregnancy rates with CF (22% per cycle, chromosomal abnormalities mainly in carriers of translocations though the proportion of cycles reaching transfer is relatively 24% per OR and 27.5% per embryo transfer) are comparable to a previous report (for the ∆F508 deletion only) of global low (68%), possibly indicating that some couples may not be suitable even for preimplantation screening because too few figures for six centres of 29% per OR and 33% per embryo transfer (Ao et al., 1996) . Also, there may be scope for karyotypically normal embryos are present. The most striking feature of the Consortium data to date, however, is the poor improvement since although 71% of diagnosed embryos were available for transfer, this was only 44% of the original cohort results with identification of sex in X-linked disease with multicolour FISH using X and Y chromosome specific probes of 2PN embryos in those cycles because of a relatively high diagnostic failure rate of 16%. There is clear evidence in along with a variable number of autosomal probes. In these cases (n ϭ 104), the pregnancy rate was only 7% per cycle, conventional IVF cycles that pregnancy rates are better when a fixed number of embryos can be selected for transfer from 8% per OR and 9% per embryo transfer. This is a major application of PGD, since it is a generic approach to over 300 a larger number of morphologically good quality embryos. This restricted choice on genetic criteria must therefore have X-linked recessive diseases and has been in development clinically for almost 10 years. Even in the early years, significant impact on pregnancy rates and extra efforts to improve diagnostic efficiency are obviously needed. The same pregnancy rates of 22% per cycle and 28.5% per embryo transfer were reported (Griffin et al., 1994) . If these cycles comments are also true of the DM series with the added problem that as an autosomal dominant only 50% of embryos are removed (Table IX) , the overall pregnancy rates for the Consortium increase to 20.5% per cycle, 21.5% per OR and on average will be unaffected. From that perspective, a pregnancy rate of 22% per embryo transfer is encouraging.
25.5% per embryo transfer which is more comparable to previous global rates (see above). Table VIII summarizes the Consortium experience using FISH to identify sex in X-linked disease and to detect various This clearly needs detailed investigation and it is already clear that, for whatever reason, some centres are simply not chromosomal abnormalities. The pregnancy rates with aneuploidy screening (25% per cycle and 29% per embryo transfer) identifying a sufficient proportion of female embryos. The reasons for this could be a combination of the increased are excellent considering that all of these couples had a poor prognosis for conventional IVF mainly because of advanced number of chromosome probes analysed in addition to the X and Y chromosomes and some centres are analysing two cells maternal age. Nevertheless, there is a case to be made that this form of PGD should be considered separately (see where possible to avoid errors resulting from chromosomal mosaicism. The problem is that this may be leading to the discussion above). Again there is good news for detection of
